Surfix Secures New Investment Round to Propel Growth

Wageningen, 4 September 2024

Surfix B.V. today announced the successful completion of a new financing round, strengthening its operational runway and setting the stage for a larger funding round in 2025. The investment was led by PhotonVentures, with equal contributions from PhotonVentures, OostNL, and two business angels.

Surfix is pioneering the development of a cutting-edge Photonic Diagnostics Platform, a multi-modal point-of-care solution offering lab-grade precision. The company’s mission is to become a key strategic partner in immunoassay co-development while providing advanced readout instruments and cartridges to the global human in vitro diagnostic (IVD) point-of-care testing (POCT) market.

Since its strategic pivot in 2021, Surfix has achieved significant technological advancements. Initial evaluations of its platform, first targeting COVID-19 diagnostics and later focusing on a sepsis multiplex (including IL-6, PCT, and CRP), have attracted interest from leading industry players exploring assay co-development opportunities. Additionally, top-tier diagnostic companies have initiated blind studies, further demonstrating confidence in Surfix’s innovative approach.

“With these critical evaluations ongoing, we have decided to extend our runway by another year,” said Jos Lunenberg, CEO of Surfix. “Achieving conclusive results from these studies will be a major milestone, unlocking key value inflection points and paving the way for a larger fundraising round in the near future.”

This investment will allow Surfix to further develop its technology and strengthen its position as a leader in photonic diagnostics, driving the next generation of rapid, accurate, and accessible point-of-care testing solutions.